News

Molecular basis for interaction between an essential protein complex and its regulator

Leah Mann
By Leah Mann
June 4, 2023

The labs of Lauren Jackson, associate professor of biological sciences and biochemistry, and Todd Graham, Stevenson Professor of Biological Sciences at the College of Arts and Science and professor of cell and developmental biology, recently published a study in the Journal of Cell Biology describing a significant interaction between an essential protein complex used for protein and lipid transport—the COPI complex—and its regulator protein.

The authors include Betty Xie and Cameron Cohen, two graduate students in the Jackson lab, and Swapneeta Date, senior scientist in the Graham lab. Together, the two groups established how COPI interacts with the regulator protein Glo3, a member of the ArfGAP protein family of enzymes. Disruptions of the interaction between COPI and Glo3 lead to deleterious effects in cells.

We sat down with Jackson to find out more about this research.

Lauren Jackson
Lauren Jackson

What issue/problem does your research address?

Our lab studies the cellular “FedEx system” that allows proteins and lipids to move between membrane-bound compartments. This work focused on COPI, which is required in all eukaryotes. Mutations in COPI are associated with multiple human diseases, including cancers and microcephalies, which are conditions in which a patient’s head is abnormally small. Pathogens, including viruses like SARS-CoV-2, also hijack COPI to take over cells.

While the field has previously established that molecules in the ArfGAP family affect COPI function, the mechanisms involved in this interaction have not been well understood. We sought to determine the basis for the interaction between COPI subunits and a specific ArfGAP protein, Glo3.

What was unique about your approach to the research?

We undertook a multi-disciplinary approach to address these questions using biochemistry, biophysics, computational artificial intelligence-based modeling, and in vivo approaches including fluorescence imaging in budding yeast. This combination of approaches allows us to use the molecular information generated from biochemical, biophysical, and computational studies to design hypotheses that could be used to test function directly in budding yeast, our model organism.

What were your findings?

We discovered a molecular “code” that explains how COPI recruits ArfGAP proteins. We identified specific amino acid residues on each protein that mediate the interaction between COPI and ArfGAP. We then tested how breaking the interaction affected the movement of transmembrane protein cargo using budding yeast as our model organism. Breaking this interaction specifically disrupted the shape of a key organelle called the Golgi, and it also misdirected specific cargo proteins to the wrong cellular location.

Figure 5 from the paper “An interaction between β′-COP and the ArfGAP, Glo3, maintains post-Golgi cargo recycling” shows β9-COP is a molecular platform on Golgi membranes.
Figure 5 from the paper “An interaction between β′-COP and the ArfGAP, Glo3, maintains post-Golgi cargo recycling” shows β9-COP is a molecular platform on Golgi membranes.

What do you hope will be achieved with the research results in the short and long terms?

Overall, many of these proteins are strongly conserved across species, which suggests our results will be relevant to human biology. This study provides a variety of molecular tools that we can use to dissect these important cellular events that drive essential membrane trafficking—the process of moving proteins and other molecules throughout the cell using membrane-bound vesicles.

What are the benefits of this research?

This research contributes to our understanding of fundamental biological processes in cellular sorting. Obtaining molecular information allows us to probe complex cellular sorting pathways so that we can understand human physiology and what goes wrong in disease states, such as in neurological disorders or cancers, when essential proteins are mutated or lost

Where is this research taking you next?

This work builds on our ongoing collaboration with Todd Graham’s lab. Together, the Jackson and Graham labs use a variety of methods to understand how the COPI/Glo3 interaction drives specific cellular sorting events (Jackson lab) and how the interaction is affected by post-translational modifications and sorting of SNAREs, a family of proteins that play essential roles in vesicle fusion events (Graham lab).

This article was written for Vanderbilt University’s School of Medicine Basic Sciences and was republished with permission. Read the original.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Leah Mann
Leah Mann

Leah Mann is a neuroscience Ph.D. candidate at Vanderbilt University, where she studies Parkinson’s disease. She enjoys communicating her research and science at large to others and making it relatable and understandable to people outside the field.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Profile

How HCMV hijacks host cells — and beyond

Aug. 12, 2025

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.